As­traZeneca and Dai­ichi Sankyo fail to win NICE rec­om­men­da­tion for En­her­tu, call for change to re­view process

The Unit­ed King­dom’s drug pric­ing watch­dog has of­fi­cial­ly de­clined to rec­om­mend As­traZeneca and Dai­ichi Sankyo’s En­her­tu for HER2-low breast can­cer in the UK, not­ing that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER